Skip to content
Peptide Atlas
All goals

Four compounds studied for gut-lining repair, barrier integrity, and gut inflammation

Researchers have studied several compounds for repairing the gut lining and calming inflammation in the digestive tract. Teduglutide is the only one with human trial approval, and it is specifically for a rare condition called short bowel syndrome. The others — lactoferrin, elafin, and KPV — are supported mostly by laboratory work, animal studies, or a mix that does not yet establish everyday gut-healing benefit in people.

The biology of this goal

The inside of your intestine is lined with a single layer of cells that both absorbs nutrients and acts as a barrier, keeping the bacteria and contents of the gut on one side and your body on the other. When this lining is damaged or inflamed, the barrier can leak and the gut cannot absorb food properly. Healing the gut means helping these lining cells grow and repair, quieting inflammation, and keeping the barrier sealed. The compounds here work on different parts of this picture: some tell the lining to grow, some block the enzymes and signals that drive inflammation, and some help defend against harmful microbes.

What the research supports

4 of 4 compounds considered

Teduglutide

Tier 1 · Human trials

Human trials report that teduglutide increases intestinal absorption and reduces the need for IV nutrition in short bowel syndrome, and it is approved for this use in the US and EU.

Teduglutide is a lab-made, longer-lasting copy of a natural gut hormone called GLP-2. It tells the cells lining the intestine to grow and repair, resist dying off, and absorb more fluid and nutrients, while also slowing stomach emptying and boosting blood flow to the gut. It is used in short bowel syndrome, where a person has lost much of their functional intestine and needs help absorbing enough to reduce IV feeding.

  • Teduglutide is approved in the US and EU as a targeted treatment for short bowel syndrome-associated intestinal failure, including patients aged one year and older who are stable after postsurgical intestinal adaptation.1,2

  • GLP-2 improves structural and functional intestinal adaptation by decelerating rapid gastric emptying, decreasing gastric hypersecretion, increasing intestinal blood flow, and promoting intestinal growth; it can induce crypt cell proliferation, inhibit epithelial apoptosis, promote repair of damaged mucosa, and regulate barrier function.1,3

  • In a 3-week phase 2 metabolic balance study, teduglutide increased intestinal wet weight absorption by approximately 700 g/day.1

  • In a phase III trial in adults dependent on parenteral support, significantly more patients on teduglutide 0.05 mg/kg/day than placebo achieved a 20% or greater reduction in weekly parenteral support volume from baseline to week 20 and maintained it to week 24, with benefits generally maintained longer term.2

What this doesn't establish

This evidence is confined to short bowel syndrome-associated intestinal failure; it does not establish benefit for everyday gut healing, general barrier leakiness, or inflammatory conditions in people with intact bowel.

Lactoferrin

Tier 1 · Human trials

Human trials and reviews report lactoferrin's effects on intestinal cell growth, iron absorption, and anti-inflammatory activity, with additional laboratory digestion data.

Lactoferrin is a natural iron-binding defence protein found in milk and other body fluids. Researchers report it can prompt the intestinal lining to grow and expand its absorptive surface, and that it has anti-inflammatory effects. It also helps the gut take up iron.

  • Lactoferrin can stimulate intestinal cell proliferation and differentiation, causing expansion of tissue mass and absorptive capacity.4

  • Oral lactoferrin treatment may have an anti-inflammatory effect on pregnant women, reducing pregnancy complications.4

  • Lactoferrin enhances intestinal absorption of iron and improves hemoglobin production.6

  • In simulated digestion, intact lactoferrin retention was similar across lactoferrin types, and peptides from digested human milk lactoferrin correlated with recombinant human lactoferrin in the intestinal phase (r between 0.63 and 0.70).5

What this doesn't establish

The reviewed human work centres on iron status, immune parameters, and pregnancy rather than direct repair of a damaged or inflamed gut lining, so a gut-healing benefit in that specific sense is not established here.

Elafin

Tier 1 · Human trials

Animal and laboratory studies suggest elafin protects the gut mucosa in conditions of acute or chronic inflammation and gluten sensitization, and researchers are considering mucosal delivery for tissue repair.

Elafin is a human protein made naturally at surfaces like the skin, lung, and gut lining. It works by blocking destructive enzymes that immune cells release during inflammation, which protects tissue from being broken down. Researchers are investigating delivering extra elafin to the gut lining to help calm inflammation and support repair.

  • Accumulating evidence has demonstrated protective effects of trappin-2/elafin in gut intestinal disorders associated with acute or chronic inflammation, or with gluten sensitization disorders.7,8

  • Researchers are considering the therapeutic potential of delivering trappin-2/elafin at the intestinal mucosa surface to ensure intestinal tissue repair.7,8

  • Elafin inhibits cathepsin S and protease-activated receptor 2 activities and reduces collagen synthesis in intestinal fibroblasts.9

What this doesn't establish

There are no completed human gut trials here; therapeutic mucosal delivery remains a proposal under discussion rather than a demonstrated treatment in people.

KPV

Tier 3 · Reported use

Animal and laboratory studies suggest KPV reduces gut inflammation, with additional lower-tier community and practitioner commentary; there are no completed human gut trials.

KPV is a tiny fragment of three amino acids taken from the tail end of a natural hormone, and it is studied mainly for calming inflammation. In gut cells it quiets the signals that drive inflammation, and because it is small it can enter inflamed gut cells through a dedicated transporter. In animal models of colitis, oral KPV reduced the severity of gut inflammation.

  • KPV reduces pro-inflammatory cytokine secretion in human intestinal epithelial cells and human T cells, acting via PepT1 expressed in immune and intestinal epithelial cells.10

  • Oral administration of KPV reduced the incidence of both DSS-induced and TNBS-induced colitis in mice, indicated by decreased pro-inflammatory cytokine expression.10

  • In TNBS-induced ulcerative colitis rats, a KPV/SH-PGA hydrogel attenuated body weight loss and disease activity index score, prevented colon shortening, lowered colonic myeloperoxidase, and recovered epithelial barrier, crypt, and goblet cell morphology.11

  • Community and practitioner commentary describes KPV blocking NF-κB and MAP kinase in intestinal cells at nanomolar amounts and being small enough to survive digestion and be absorbed intact for oral use.12

What this doesn't establish

All efficacy data are from cell cultures and rodent colitis models, so KPV's effect on barrier integrity or inflammation in humans is not established.

How they work together

Check this stack

These compounds act on different arms of gut repair and are generally described as complementary. Teduglutide drives epithelial growth and barrier repair through the GLP-2 receptor, while elafin protects that same lining by neutralizing destructive proteases and calming inflammation — different mechanisms toward the same goal. Elafin and KPV both restrain inflammation at mucosal surfaces largely by limiting NF-κB signaling, but by different means: KPV suppresses cytokines while elafin blocks tissue-destroying proteases. Lactoferrin and elafin are described as two arms of innate mucosal immunity, lactoferrin sequestering iron from microbes and elafin blocking neutrophil proteases. Pairing an inflammation-dampener like KPV with a growth signal like teduglutide, or with lactoferrin's antimicrobial defence, is described as logically complementary, though the teduglutide-plus-KPV and lactoferrin-plus-KPV combinations are only anecdotally supported. There is no documented interaction between teduglutide and lactoferrin in our data, which is an absence of evidence rather than a clearance.

  • Teduglutide + Elafin

    May be complementary

    Teduglutide drives intestinal epithelial growth and barrier repair through the GLP-2 receptor, while elafin protects that same mucosa by neutralizing destructive proteases and calming inflammation. Different mechanisms both supporting gut mucosal integrity and repair.

    Not fully established

    Both peptides' mechanisms clearly support mucosal_repair and tissue_repair functions through distinct but complementary pathways. Elafin inhibits neutrophil serine proteases (elastase, proteinase 3) and modulates NF-κB/inflammatory signaling to protect mucosal tissue from enzymatic destruction. Teduglutide activates GLP-2 receptor signaling to promote intestinal epithelial growth, proliferation, and barrier function. The mechanisms describe non-overlapping approaches to the same tissue outcome: one protective/anti-degradative, one growth/regenerative. Both are explicitly tagged with mucosal_repair and tissue_repair in their approved tags, and the explanation accurately reflects how their distinct molecular mechanisms would work synergistically on intestinal mucosa.

  • Lactoferrin + Elafin

    May be complementary

    Lactoferrin defends by sequestering iron away from microbes and calming inflammation, while elafin blocks neutrophil serine proteases. They are two arms of innate mucosal immunity working through different mechanisms toward the same goal of infection control and reduced inflammatory tissue damage.

    Not fully established

    Both peptides' mechanisms clearly establish the three claimed shared dimensions. (1) Innate_immune: Elafin targets neutrophil elastase and proteinase 3 (neutrophil serine proteases) and modulates NF-κB and IRF3/IFN-β antiviral signalling; Lactoferrin modulates inflammatory, humoral and cellular immune responses and has antiviral activity. (2) Antimicrobial: Elafin has documented antimicrobial activity against bacteria and fungi; Lactoferrin has broad-spectrum antimicrobial activity (antibacterial, antifungal). (3) Anti_inflammatory: Elafin is explicitly tagged anti_inflammatory with NF-κB pathway modulation; Lactoferrin is explicitly tagged anti_inflammatory with modulation of inflammatory immune responses. The explanation accurately describes their distinct mechanisms (iron sequestration vs. protease inhibition) converging on mucosal defense, which is consistent with the 'complementary' relationship type and the mechanisms provided. The proposed relationship is well-justified by the material.

  • Elafin + KPV

    May be complementary

    Both dampen inflammation at mucosal surfaces largely by restraining NF-κB signaling, but by different means: KPV (an α-MSH fragment) suppresses inflammatory cytokines and stabilizes IκBα, while elafin blocks tissue-destroying proteases. In a gut/mucosal setting they address inflammation and barrier protection from complementary angles.

    Not fully established

    The mechanisms clearly establish complementary roles in mucosal inflammation control. Both peptides share three documented dimensions: (1) innate_immune function—elafin via protease inhibition and antimicrobial activity, KPV via immunomodulation and cytokine suppression; (2) anti_inflammatory effects—elafin through NF-κB modulation and tissue protection, KPV through TNF-α/IL-1β/IL-6 suppression; (3) NF-κB_modulation—elafin via NF-κB pathway modulation (src-17, src-23), KPV via IκBα stabilization and IKK complex inhibition. The explanation accurately characterizes their distinct mechanisms: KPV acts through cytokine suppression and IκBα stabilization, while elafin acts through protease inhibition and tissue protection. Both target mucosal barrier integrity and inflammation resolution in overlapping contexts (gut/mucosal surfaces), making them genuinely complementary rather than redundant. The proposed relationship type and shared dimensions are directly supported by the provided mechanism material.

  • Teduglutide + KPV

    No known conflict in the research

    Both target the gut lining but by entirely different routes: KPV calms mucosal inflammation (NF-κB suppression, reduced colitis severity in animal models), while teduglutide is a GLP-2 agonist that stimulates intestinal epithelial growth and repair. Pairing an inflammation-dampener with a growth/repair signal is a logically complementary approach to restoring a damaged gut barrier, though this combination is only anecdotally supported.

    Not fully established

    Both peptides' mechanisms clearly establish the shared dimension of gut_barrier_integrity through distinct pathways: KPV suppresses mucosal inflammation (NF-κB inhibition, reduced colitis severity, mucosal barrier repair in animal models) while teduglutide promotes epithelial growth, proliferation, and mucosal repair via GLP-2 receptor signaling. The proposed relationship as 'complementary' is justified—they address barrier integrity through mechanistically different routes (inflammation resolution vs. tissue growth/repair), which logically complement each other. The explanation accurately reflects both mechanisms' documented effects on the gut barrier, and the caveat about anecdotal support appropriately acknowledges the lack of direct clinical evidence for the combination.

  • Lactoferrin + KPV

    No known conflict in the research

    Lactoferrin provides direct antimicrobial defence and iron sequestration at mucosal surfaces, while KPV suppresses the inflammatory cytokine cascade. Both are oriented toward gut/mucosal health from different mechanisms, making them a plausible complementary pair for barrier and microbiome support.

    Not fully established

    Both peptides' mechanisms clearly establish the claimed shared dimensions. KPV is explicitly tagged with innate_immune and anti_inflammatory, with documented NF-κB suppression, cytokine reduction (TNF-alpha, IL-1beta, IL-6), and mucosal barrier repair effects. Lactoferrin is similarly tagged innate_immune and anti_inflammatory, with documented broad-spectrum antimicrobial activity, iron homeostasis, and inflammatory immune response modulation. The proposed relationship correctly identifies that they operate through distinct mechanisms (KPV via intracellular signaling/cytokine suppression; lactoferrin via direct antimicrobial action and iron sequestration) yet converge on shared functional outcomes relevant to mucosal health. The explanation accurately reflects the mechanism material: KPV's inflammatory cytokine cascade suppression and lactoferrin's direct antimicrobial/iron-binding defense are mechanistically complementary rather than redundant. Both mechanisms support gut/mucosal barrier integrity from different angles, justifying the complementary classification.

  • Teduglutide + Lactoferrin

    No documented interaction in our data — that is not a safety clearance.

Sources

Ordered as cited above.

  1. New approaches to the treatments of short bowel syndrome-associated intestinal failure.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov
  2. Teduglutide: A Review in Short Bowel Syndrome.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov
  3. An updated overview of glucagon-like peptide-2 analog trophic therapy for short bowel syndrome in adults(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  4. Nutritional roles of lactoferrin.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov
  5. Digestive Profiles of Human Milk, Recombinant Human and Bovine Lactoferrin: Comparing the Retained Intact Protein and Peptide Release - PubMed(opens in a new tab)
    Tier 2Web · pubmed.ncbi.nlm.nih.gov
  6. A Randomized, Double-Blind, Controlled Trial to Assess the Effects of Lactoferrin at Two Doses vs. Active Control on Immunological and Safety Parameters in Healthy Adults | medRxiv(opens in a new tab)
    Tier 1Web · medrxiv.org
  7. Elafin and its precursor trappin‐2: What is their therapeutic potential for intestinal diseases?(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  8. Elafin and its precursor trappin-2: What is their therapeutic potential for intestinal diseases?(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  9. Elafin Reverses Intestinal Fibrosis by Inhibiting Cathepsin S-Mediated ...(opens in a new tab)
    Tier 2Web · cmghjournal.org
  10. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  11. Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  12. KPV Peptide: Benefits, Dosage & Safety (2026 Guide)(opens in a new tab)
    Tier 3Web · peptidemind.com

This brief reports what published research says about these compounds. It is information, not medical advice, and not a recommendation to use anything described here. Evidence quality varies by compound and is labelled throughout. Talk to a qualified clinician before acting on any of it.